Recruiting
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis - IM011-1105
Mis à jour:
22 juillet, 2024
|
ClinicalTrials.gov
Résumé imprimable
Détails de l’essai
-
Sexe(s)
-
18+
Tranche d’âge
-
1
Site(s)
-
Recruiting
Options de traitement
Principaux critères d’éligibilité
Inclusion Criteria: - Have been diagnosed with plaque psoriasis by a dermatologist - Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast) - Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes Exclusion Criteria: - Currently participating in an interventional clinical trial (does not include observational registry or study)